
Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals, Inc. (SPPI) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
sppi · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 4 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Spectrum Pharmaceuticals, Inc.You SPPI | $210M | N/A | — | -$0.43 |
CARGO Therapeutics, Inc. Common Stock CRGX | $216M | N/A | — | -$3.72 |
Inozyme Pharma, Inc. INZY | $258M | N/A | — | -$1.62 |
LENZ Therapeutics, Inc. LENZ | $217M | N/A | — | -$2.85 |
LakeShore Biopharma Co., Ltd LSB | $26M | N/A | — | -$0.94 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Spectrum Pharmaceuticals, Inc. (SPPI) measures how much investors pay for each dollar of the company's trailing earnings. SPPI's current PE ratio of N/A is calculated by dividing its stock price of $1.02 by its TTM earnings per share of -$0.43.
Frequently asked questions
SPPI pe ratio · 6 questionsSPPI's current PE ratio is N/A as of 2026-06-09, based on a stock price of $1.02 and TTM EPS of -$0.43. Data sourced from Financial Modeling Prep via SPPI's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Spectrum Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09